Eikon is a pioneering drug discovery and development company that leverages superior engineering and high-performance computing to analyze single molecule protein behavior in living cells. We are engineering a battery of innovative tools and technologies for biological exploration in drug discovery and beyond.
We believe the future of drug discovery will incorporate live cell imaging of single protein movement in cells. Eikon is pioneering a new method of drug discovery based on tracking and measuring these movements of individual proteins in living cells. The ability to assess protein dynamics will reveal novel biological mechanisms of action, providing new therapeutic approaches that will address both existing and novel drug targets. These insights will form the basis for innovative new therapies for grievous illness.
We are building a world-class team of experts in engineering, computation, biology, medicinal chemistry, pharmacology and clinical studies which will enable us to invent innovative therapies that will improve and extend life.
Our therapeutic platform is rooted in super-resolution fluorescence microscopy, developed by Eikon co-founder Eric Betzig, for which he shared the 2014 Nobel Prize in Chemistry. Our robotic systems permit exquisitely precise measurement of the dynamic behavior of individual protein molecules in living cells, on a massive scale.